Skip to main content
Erschienen in: Endocrine 1/2021

09.08.2020 | Original Article

A mutation in NOTCH2 gene first associated with Hajdu–Cheney syndrome in a Greek family: diversity in phenotype and response to treatment

Erschienen in: Endocrine | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Hajdu–Cheney Syndrome (HCS) is a rare genetic autosomal dominant disorder, characterized by distinctive facial features, acroosteolysis, and severe osteoporosis. Very rarely HCS is associated with polycystic kidney disease, splenomegaly or Crohn’s disease (CD). It is caused by gain-of-function mutations in NOTCH2 gene. Treatment with bisphosphonates or denosumab is reported to result in BMD increase.

Objective

We report a mutation in exon 34 of NOTCH2 gene, in a Greek pedigree, with diverse phenotypes among members.

Description of the pedigree

The 48-year-old mother had a history of a T12 vertebral fracture, postpartum at the age of 21 and two subsequent uneventful full-term pregnancies and never received treatment. Her 29-year-old son, presented with severe osteoporosis and multiple morphological vertebral fractures. Her 21-year-old daughter had recurrent vertebral fractures starting at 10 years of age. At 17 years, she developed severe CD, resistant to treatment with biologic agents, and functional hypothalamic hypogonadism. One male pedigree died of cystic fibrosis. All subjects bore the typical facial characteristics and acroosteolysis, while none had splenomegaly or renal defects. Zoledronate infusion led to BMD increase.

Genetic testing

Mutation in c.6758 G > A (NM_008163.1), leading to a Trp2253Ter replacement. This mutation has been reported as possibly pathogenic (SCV000620308), but not in association with HCS.

Conclusions

Bone involvement can present with diverse severity in the same pedigree, ranging from low BMD to multiple fragility fractures. Antiresorptive therapy improves BMD, but its anti-fracture efficacy remains to be shown. The presence of CD might indicate the significant role of NOTCH2 signaling in different tissues.
Literatur
1.
Zurück zum Zitat E. Canalis, Clinical and experimental aspects of notch receptor signaling: Hajdu-Cheney syndrome and related disorders. Metab. Clin. Exp. 80, 48–56 (2018).CrossRef E. Canalis, Clinical and experimental aspects of notch receptor signaling: Hajdu-Cheney syndrome and related disorders. Metab. Clin. Exp. 80, 48–56 (2018).CrossRef
2.
Zurück zum Zitat J. Reichrath, S. Reichrath, Notch Pathway and Inherited Diseases: Challenge and Promise. Adv. Exp. Med. Biol 1218, 159–187 (2020).CrossRef J. Reichrath, S. Reichrath, Notch Pathway and Inherited Diseases: Challenge and Promise. Adv. Exp. Med. Biol 1218, 159–187 (2020).CrossRef
3.
Zurück zum Zitat Y. Narumi, B.J. Min, K. Shimizu, I. Kazukawa, K. Sameshima, K. Nakamura, T. Kosho, Y. Rhee, Y.S. Chung, O.H. Kim, Y. Fukushima, W.Y. Park, G. Nishimura, Clinical consequences in truncating mutations in exon 34 of NOTCH2: Report of six patients with Hajdu-Cheney syndrome and a patient with serpentine fibula polycystic kidney syndrome. Am. J. Med. Genet., Part A 161, 518–526 (2013).CrossRef Y. Narumi, B.J. Min, K. Shimizu, I. Kazukawa, K. Sameshima, K. Nakamura, T. Kosho, Y. Rhee, Y.S. Chung, O.H. Kim, Y. Fukushima, W.Y. Park, G. Nishimura, Clinical consequences in truncating mutations in exon 34 of NOTCH2: Report of six patients with Hajdu-Cheney syndrome and a patient with serpentine fibula polycystic kidney syndrome. Am. J. Med. Genet., Part A 161, 518–526 (2013).CrossRef
4.
Zurück zum Zitat E. Canalis, S. Zanotti, Hajdu-Cheney Syndrome, a Disease Associated with NOTCH2 Mutations. Curr. Osteoporos. Rep. 14, 126–131 (2016).CrossRef E. Canalis, S. Zanotti, Hajdu-Cheney Syndrome, a Disease Associated with NOTCH2 Mutations. Curr. Osteoporos. Rep. 14, 126–131 (2016).CrossRef
5.
Zurück zum Zitat G. Adami, M. Rossini, D. Gatti, G. Orsolini, L. Idolazzi, O. Viapiana, A. Scarpa, E. Canalis, Hajdu Cheney Syndrome; report of a novel NOTCH2 mutation and treatment with denosumab. Bone. 92, 150–156 (2016).CrossRef G. Adami, M. Rossini, D. Gatti, G. Orsolini, L. Idolazzi, O. Viapiana, A. Scarpa, E. Canalis, Hajdu Cheney Syndrome; report of a novel NOTCH2 mutation and treatment with denosumab. Bone. 92, 150–156 (2016).CrossRef
6.
Zurück zum Zitat F.E. McKiernan, Integrated anti-remodeling and anabolic therapy for the osteoporosis of Hajdu-Cheney syndrome. Osteoporos. Int. 18, 245–249 (2007).CrossRef F.E. McKiernan, Integrated anti-remodeling and anabolic therapy for the osteoporosis of Hajdu-Cheney syndrome. Osteoporos. Int. 18, 245–249 (2007).CrossRef
7.
Zurück zum Zitat H. Fukushima, A. Nakao, F. Okamoto, M. Shin, H. Kajiya, S. Sakano, A. Bigas, E. Jimi, K. Okabe, The Association of Notch2 and NF- B Accelerates RANKL-Induced Osteoclastogenesis. Mol. Cell. Biol. 28, 6402–6412 (2008).CrossRef H. Fukushima, A. Nakao, F. Okamoto, M. Shin, H. Kajiya, S. Sakano, A. Bigas, E. Jimi, K. Okabe, The Association of Notch2 and NF- B Accelerates RANKL-Induced Osteoclastogenesis. Mol. Cell. Biol. 28, 6402–6412 (2008).CrossRef
8.
Zurück zum Zitat J. Yu, E. Canalis, The Hajdu Cheney mutation sensitizes mice to the osteolytic actions of tumor necrosis factor α. J. Biol. Chem. 294, 14203–14214 (2019).CrossRef J. Yu, E. Canalis, The Hajdu Cheney mutation sensitizes mice to the osteolytic actions of tumor necrosis factor α. J. Biol. Chem. 294, 14203–14214 (2019).CrossRef
9.
10.
Zurück zum Zitat M.J. Hilton, X. Tu, X. Wu, S. Bai, H. Zhao, T. Kobayashi, H.M. Kronenberg, S.L. Teitelbaum, F.P. Ross, R. Kopan, F. Long, Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat. Med. 14, 306–314 (2008).CrossRef M.J. Hilton, X. Tu, X. Wu, S. Bai, H. Zhao, T. Kobayashi, H.M. Kronenberg, S.L. Teitelbaum, F.P. Ross, R. Kopan, F. Long, Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat. Med. 14, 306–314 (2008).CrossRef
11.
Zurück zum Zitat M. Descartes, K. Rojnueangnit, L. Cole, A. Sutton, S.L. Morgan, L. Patry, M.E. Samuels, Hajdu-Cheney syndrome: Phenotypical progression with de-novo NOTCH2 mutation. Clin. Dysmorphol. 23, 88–94 (2014).CrossRef M. Descartes, K. Rojnueangnit, L. Cole, A. Sutton, S.L. Morgan, L. Patry, M.E. Samuels, Hajdu-Cheney syndrome: Phenotypical progression with de-novo NOTCH2 mutation. Clin. Dysmorphol. 23, 88–94 (2014).CrossRef
12.
Zurück zum Zitat W.M. Drake, M.P. Hiorns, D.L. Kendler, Hadju-Cheney syndrome: Response to therapy with bisphosphonates in two patients. J. Bone Miner. Res. 18, 131–133 (2003).CrossRef W.M. Drake, M.P. Hiorns, D.L. Kendler, Hadju-Cheney syndrome: Response to therapy with bisphosphonates in two patients. J. Bone Miner. Res. 18, 131–133 (2003).CrossRef
13.
Zurück zum Zitat S. Hwang, D.Y. Shin, S.H. Moon, E.J. Lee, S.K. Lim, O.H. Kim, Y. Rhee, Effect of Zoledronic Acid on Acro-Osteolysis and Osteoporosis in a Patient with Hajdu-Cheney Syndrome. Yonsei Med. J. 52, 543–546 (2011).CrossRef S. Hwang, D.Y. Shin, S.H. Moon, E.J. Lee, S.K. Lim, O.H. Kim, Y. Rhee, Effect of Zoledronic Acid on Acro-Osteolysis and Osteoporosis in a Patient with Hajdu-Cheney Syndrome. Yonsei Med. J. 52, 543–546 (2011).CrossRef
14.
Zurück zum Zitat J.F.H. Pittaway, C. Harrison, Y. Rhee, M. Holder-Espinasse, A.E. Fryer, T. Cundy, W.M. Drake, M.D. Irving, Bisphosphonate therapy for spinal osteoporosis in Hajdu-Cheney syndrome - New data and literature review. Orphanet J. Rare Dis. 13, 47 (2018). J.F.H. Pittaway, C. Harrison, Y. Rhee, M. Holder-Espinasse, A.E. Fryer, T. Cundy, W.M. Drake, M.D. Irving, Bisphosphonate therapy for spinal osteoporosis in Hajdu-Cheney syndrome - New data and literature review. Orphanet J. Rare Dis. 13, 47 (2018).
15.
Zurück zum Zitat F.E. McKiernan, Integrated anti-remodeling and anabolic therapy for the osteoporosis of Hajdu-Cheney syndrome: 2-Year follow-up. Osteoporos. Int. 19, 379–380 (2008).CrossRef F.E. McKiernan, Integrated anti-remodeling and anabolic therapy for the osteoporosis of Hajdu-Cheney syndrome: 2-Year follow-up. Osteoporos. Int. 19, 379–380 (2008).CrossRef
16.
Zurück zum Zitat A. Galli-Tsinopoulou, I. Kyrgios, S. Giza, E.Z. Giannopoulou, I. Maggana, N. Laliotis, Two-year cyclic infusion of pamidronate improves bone mass density and eliminates risk of fractures in a girl with osteoporosis due to Hajdu-Cheney syndrome. Minerva Endocrinologica. 37, 283–289 (2012).PubMed A. Galli-Tsinopoulou, I. Kyrgios, S. Giza, E.Z. Giannopoulou, I. Maggana, N. Laliotis, Two-year cyclic infusion of pamidronate improves bone mass density and eliminates risk of fractures in a girl with osteoporosis due to Hajdu-Cheney syndrome. Minerva Endocrinologica. 37, 283–289 (2012).PubMed
18.
Zurück zum Zitat L. Graversen, M.M. Handrup, M. Irving, H. Hove, B.R. Diness, L. Risom, D. Svaneby, M.M. Aagaard, I. Vogel, H. Gjørup, M. Davidsen, M.B. Hellfritzsch, E. Lauridsen, P.A. Gregersen, Phenotypic presentations of Hajdu-Cheney syndrome according to age – 5 distinct clinical presentations. Eur. J. Med. Genet. 63, 103650 (2020). L. Graversen, M.M. Handrup, M. Irving, H. Hove, B.R. Diness, L. Risom, D. Svaneby, M.M. Aagaard, I. Vogel, H. Gjørup, M. Davidsen, M.B. Hellfritzsch, E. Lauridsen, P.A. Gregersen, Phenotypic presentations of Hajdu-Cheney syndrome according to age – 5 distinct clinical presentations. Eur. J. Med. Genet. 63, 103650 (2020).
19.
Zurück zum Zitat J. Jirečková, M. Magner, L. Lambert, A. Baxová, A. Leiská, L. Kopečková, L. Fajkusová, J. Zeman, The Age Dependent Progression of Hajdu-Cheney Syndrome in Two Families. Prague Med. Rep. 119, 156–164 (2018).CrossRef J. Jirečková, M. Magner, L. Lambert, A. Baxová, A. Leiská, L. Kopečková, L. Fajkusová, J. Zeman, The Age Dependent Progression of Hajdu-Cheney Syndrome in Two Families. Prague Med. Rep. 119, 156–164 (2018).CrossRef
20.
Zurück zum Zitat M.J. Gray, C.A. Kim, D.R. Bertola, P.R. Arantes, H. Stewart, M.A. Simpson, M.D. Irving, S.P. Robertson, Serpentine fibula polycystic kidney syndrome is part of the phenotypic spectrum of Hajdu-Cheney syndrome. Eur. J. Hum. Genet. 20, 122–124 (2012).CrossRef M.J. Gray, C.A. Kim, D.R. Bertola, P.R. Arantes, H. Stewart, M.A. Simpson, M.D. Irving, S.P. Robertson, Serpentine fibula polycystic kidney syndrome is part of the phenotypic spectrum of Hajdu-Cheney syndrome. Eur. J. Hum. Genet. 20, 122–124 (2012).CrossRef
21.
Zurück zum Zitat J. Chacko, J. Akhter, Hajdu-Cheney Syndrome Presenting with Extensive Lung Disease with Alveolar Cholesterol Granulomas. Ann. Clin. Pathol. 6, 1140 (2018). J. Chacko, J. Akhter, Hajdu-Cheney Syndrome Presenting with Extensive Lung Disease with Alveolar Cholesterol Granulomas. Ann. Clin. Pathol. 6, 1140 (2018).
22.
Zurück zum Zitat D. Ortiz-Masiá, J. Cosín-Roger, S. Calatayud, C. Hernández, R. Alós, J. Hinojosa, J.V. Esplugues, M.D. Barrachina, M1 macrophages activate notch signalling in epithelial cells: Relevance in Crohn’s disease. J. Crohn’s Colitis. 10, 582–592 (2016). D. Ortiz-Masiá, J. Cosín-Roger, S. Calatayud, C. Hernández, R. Alós, J. Hinojosa, J.V. Esplugues, M.D. Barrachina, M1 macrophages activate notch signalling in epithelial cells: Relevance in Crohn’s disease. J. Crohn’s Colitis. 10, 582–592 (2016).
23.
Zurück zum Zitat E. Canalis, A. Sanjay, J. Yu, S. Zanotti, An antibody to Notch2 reverses the osteopenic phenotype of hajdu-cheney mutant male mice. Endocrinology. 158, 730–742 (2017).CrossRef E. Canalis, A. Sanjay, J. Yu, S. Zanotti, An antibody to Notch2 reverses the osteopenic phenotype of hajdu-cheney mutant male mice. Endocrinology. 158, 730–742 (2017).CrossRef
24.
Zurück zum Zitat S. Sakka, R.I. Gafni, J.H. Davies, B. Clarke, P. Tebben, M. Samuels, V. Saraff, K. Klaushofer, N. Fratzl-Zelman, P. Roschger, F. Rauch, W. Högler, Bone structural characteristics and response to bisphosphonate treatment in children with hajdu-cheney syndrome. J. Clin. Endocrinol. Metab. 102, 4163–4172 (2017).CrossRef S. Sakka, R.I. Gafni, J.H. Davies, B. Clarke, P. Tebben, M. Samuels, V. Saraff, K. Klaushofer, N. Fratzl-Zelman, P. Roschger, F. Rauch, W. Högler, Bone structural characteristics and response to bisphosphonate treatment in children with hajdu-cheney syndrome. J. Clin. Endocrinol. Metab. 102, 4163–4172 (2017).CrossRef
25.
Zurück zum Zitat S.Y. Lee, F. Long, Notch signaling suppresses glucose metabolism in mesenchymal progenitors to restrict osteoblast differentiation. J. Clin. Invest. 128, 5573–5586 (2018). S.Y. Lee, F. Long, Notch signaling suppresses glucose metabolism in mesenchymal progenitors to restrict osteoblast differentiation. J. Clin. Invest. 128, 5573–5586 (2018).
26.
Zurück zum Zitat J. Tao, M.M. Jiang, L. Jiang, J.S. Salvo, H.C. Zeng, B. Dawson, T.K. Bertin, P.H. Rao, R. Chen, L.A. Donehower, F. Gannon, B.H. Lee, Notch Activation as a Driver of Osteogenic Sarcoma. Cancer Cell. 26, 390–401 (2014). J. Tao, M.M. Jiang, L. Jiang, J.S. Salvo, H.C. Zeng, B. Dawson, T.K. Bertin, P.H. Rao, R. Chen, L.A. Donehower, F. Gannon, B.H. Lee, Notch Activation as a Driver of Osteogenic Sarcoma. Cancer Cell. 26, 390–401 (2014).
Metadaten
Titel
A mutation in NOTCH2 gene first associated with Hajdu–Cheney syndrome in a Greek family: diversity in phenotype and response to treatment
Publikationsdatum
09.08.2020
Erschienen in
Endocrine / Ausgabe 1/2021
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02446-7

Weitere Artikel der Ausgabe 1/2021

Endocrine 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.